TransMedics Group: Buy Rating Reaffirmed on Durable Growth, OCS Platform Uptake, and Emerging Clinical and Geographic Catalysts

TransMedics Group, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on the stock and has a $148.00 price target.

William Plovanic has given his Buy rating due to a combination of factors tied to TransMedics Group’s durable growth profile and upcoming catalysts. While he modestly reduced his near-term Q4/25 revenue forecast after reviewing aviation and transplant market data, he emphasizes that this adjustment reflects timing and mix, not a deterioration in the underlying business. He notes that the overall heart transplant market recovery was softer than anticipated and that DCD heart volumes, which are particularly important for TransMedics, grew more slowly than DCD lung and liver. Even with these revisions, he maintains confidence in the company’s trajectory and leaves longer-term 2026 estimates and valuation unchanged, underscoring that his fundamental thesis remains intact.
Plovanic highlights several reasons for his constructive stance, including the expected impact of the heart and lung IDE programs, which should drive higher utilization of the company’s OCS platform and potentially demonstrate clinical advantages versus traditional transplant approaches. He also points to European expansion as an additional avenue for upside beyond current expectations. In his view, TransMedics operates a differentiated product, service, and logistics model that creates a strong competitive moat and supports both revenue and earnings growth. Reflecting on a year in which the share price nearly doubled and the company remained a focal point of investor interest, he continues to see attractive risk‑reward supported by multiple growth drivers and near‑term clinical and regulatory milestones, justifying his Buy recommendation.

In another report released on January 12, TipRanks – Google also reiterated a Buy rating on the stock with a $156.00 price target.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.